High-molecular-weight aggregates in repackaged bevacizumab

Retina

Volumn 30, Issue 6, 2010, Pages 887-892

  Kahook, Malik Y ^a   Liu, Lu ^b   Ruzycki, Philip ^a   Mandava, Naresh ^a   Carpenter, John F ^b   Petrash, J Mark ^a   Ammar, David A ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; IMMUNOGLOBULIN HEAVY CHAIN; PLACEBO;

ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL PERMEATION CHROMATOGRAPHY; IMAGING; INTRAOCULAR PRESSURE; MOLECULAR WEIGHT; PARTICULATE MATTER; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN AGGREGATION; PROTEIN CONTENT; PROTEIN DEGRADATION; RETINA NEOVASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHROMATOGRAPHY, GEL; DRUG PACKAGING; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; MICROFLUIDIC ANALYTICAL TECHNIQUES; MOLECULAR WEIGHT; PARTICULATE MATTER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953358874     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181d50cea     Document Type: Article

References (22)

1. Bressler NM. Antiangiogenic approaches to age-related macular degeneration today. Ophthalmology 2009;116:S15-S23.
2. Ciulla TA, Rosenfeld PJ. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol 2009;20:158-165.
3. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-1349.
4. Landa G, Amde W, Doshi V, et al. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration. Ophthalmologica 2009;223:370-375.
5. Bakri SJ, McCannel CA, Edwards AO, Moshfeghi DM. Persistent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol 2008;246:955-958.
6. KahookMY, Kimura AE,Wong LJ, Ammar DA, Maycotte MA, Mandava N. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging 2009;40:293-295.
7. Carver J, Bouska C, Corey R. Avastin and Risk of Glaucoma. Retina Congress 2009 New York, September 30-October 4, 2009. New York, NY. Abstract.
8. Jalil A, Fenerty C, Charles S. Intravitreal bevacizumab (Avastin) causing acute glaucoma: an unreported complication. Eye 2007;21:1541.
9. Michaelsen TE, Lofsgaard MF, Aase A, Heyman B. Unexpected interaction of some anti-TNP hybridoma antibodies with Superose HPLC gel filtration resins. J Immunol Methods 1992;146:9-16.
10. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006;113:633.el-e4.
11. Bakri SJ, Snyder MR, Pulido JS, McCannel CA, Weiss WT, Singh RJ. Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing. Retina 2006;26: 519-522.
12. Chi EY, Krishnan S, Randolph TW, Carpenter JF. Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res 2003;20:1325-1336.
13. Mahler HC, Friess W, Grauschopf U, Kiese S. Protein aggregation: pathways, induction factors and analysis. J Pharm Sci 2009;98:2909-2934.
14. Kerwin BA. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways. J Pharm Sci 2008;97:2924-2935.
15. Mahler HC, Senner F, Maeder K, Mueller R. Surface activity of a monoclonal antibody. J Pharm Sci 2009;98: 4525-4533.
16. Thirumangalathu R, Krishnan S, Ricci MS, Brems DN, Randolph TW, Carpenter JF. Silicone oil- and agitationinduced aggregation of a monoclonal antibody in aqueous solution. J Pharm Sci 2009;98:3167-3181.
17. Bee JS, Chui D, Sawicki S, et al. Monoclonal antibody inter actions with micro- and nanoparticles: adsorption, aggregation and accelerated stress studies. J Pharm Sci 2009;98:3218-3238.
18. Akers MJ, Nail SL. Development and Manufacture of Protein Pharmaceuticals. 1st ed. New York: Kluwer Academic/Plenum Publishers; 2002.
19. Mueller R, Karle A, Vogt A, et al. Evaluation of the immunostimulatory potential of stopper extractables and leachables by using dendritic cells as readout. J Pharm Sci 2009;98:3548-3561.
20. GeorgopoulosM, Polak K, Prager F, Prunte C, Schmidt-Erfurth U. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol 2009;93:457-462.
21. Schwartz A. Chronic open-angle glaucoma secondary to rhegmatogenous retinal detachment. Trans Am Ophthalmol Soc 1972;70:178-189.
22. Weber AJ, Zelenak D. Experimental glaucoma in the primate induced by latex microspheres. J Neurosci Methods 2001;111: 39-48.